UroLift®前列腺尿道悬吊术在西班牙的临床应用：关于治疗与尿流梗阻相关且继发于良性前列腺增生（BPH）的下尿路症状的共识
Clinical application of the UroLift® prostatic urethral lift in Spain: consensus on the treatment of lower urinary tract symptoms associated with urinary flow obstruction and secondary to benign prostatic hyperplasia (BPH).
作者信息
Fernández Arjona M, López Martín L, Herranz Fernández L M, Sinues Ojas B, Campá Bortoló J M, Extramiana Cameno J, López Alcina E, Povo Martín I, Budía Alba A, Ordaz Jurado G, Osca García J M, Perán Teruel M, Gimeno Argente V, Navarro Beltrán A, Benejam Gual J, Hernández Martínez Y E, González Enguita C
机构信息
Servicio de Urología, Hospital Universitario del Henares, Madrid, Spain.
Servicio de Urología, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
出版信息
Actas Urol Esp (Engl Ed). 2024 Dec;48(10):732-738. doi: 10.1016/j.acuroe.2024.09.004. Epub 2024 Sep 23.
Benign prostatic hyperplasia (BPH) is an increasingly common pathology in the adult male. BPH increases after the age of 40-45 years, and its management consumes an enormous amount of resources. The UroLift® System is an approved technology designed to treat lower urinary tract symptoms (LUTS) secondary to BPH and is used to perform the prostatic urethral lift (PUL) procedure. Various urology specialists in Spain with experience in PUL have prepared this consensus document. Endorsed by the Spanish Urology Association, its information is based on the most recent findings. The main objective of this document is to disseminate the consensus recommendations among all professionals treating patients with LUTS/BPH. Both primary care physicians and urologists can assess and offer PUL as an effective, minimally invasive treatment.
良性前列腺增生（BPH）在成年男性中是一种日益常见的病症。BPH在40 - 45岁之后发病率上升，其治疗耗费大量资源。UroLift®系统是一种经批准用于治疗继发于BPH的下尿路症状（LUTS）的技术，用于实施前列腺尿道悬吊（PUL）手术。西班牙多位有PUL经验的泌尿外科专家编写了这份共识文件。该文件得到西班牙泌尿外科协会的认可，其信息基于最新研究结果。本文献的主要目的是在所有治疗LUTS/BPH患者的专业人员中传播共识建议。初级保健医生和泌尿外科医生均可评估并提供PUL作为一种有效、微创的治疗方法。
Zotero 插件